Literature DB >> 35419485

Genomic studies indicate a novel combination therapy for follicular lymphoma.

Elisa Oricchio1,2, Hans-Guido Wendel1.   

Abstract

Follicular lymphoma (FL) is an incurable form of B-cell lymphoma. Genomic alterations that inactivate RB signaling are surprisingly common in indolent FL. We show that FLs that are positive for phosphorylated RB respond to dual CDK4/BCL2 inhibition. Our results imply that RB phosphorylation identifies patients likely to benefit from such dual intervention.
© 2016 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Bcl2; cell cycle; follicular lymphoma; therapy

Year:  2014        PMID： 35419485      PMCID： PMC8997257          DOI： 10.4161/23723548.2014.969640

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Genetics of follicular lymphoma transformation.

Authors:  Laura Pasqualucci; Hossein Khiabanian; Marco Fangazio; Mansi Vasishtha; Monica Messina; Antony B Holmes; Peter Ouillette; Vladimir Trifonov; Davide Rossi; Fabrizio Tabbò; Maurilio Ponzoni; Amy Chadburn; Vundavalli V Murty; Govind Bhagat; Gianluca Gaidano; Giorgio Inghirami; Sami N Malek; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Cell Rep       Date:  2014-01-02       Impact factor: 9.423

2.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Authors:  John P Leonard; Ann S LaCasce; Mitchell R Smith; Ariela Noy; Lucian R Chirieac; Scott J Rodig; Jian Q Yu; Shankar Vallabhajosula; Heiko Schoder; Patricia English; Donna S Neuberg; Peter Martin; Michael M Millenson; Scott A Ely; Rachel Courtney; Naveed Shaik; Keith D Wilner; Sophia Randolph; Annick D Van den Abbeele; Selina Y Chen-Kiang; Jeffrey T Yap; Geoffrey I Shapiro
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

Authors:  Elisa Oricchio; Gouri Nanjangud; Andrew L Wolfe; Jonathan H Schatz; Konstantinos J Mavrakis; Man Jiang; Xiaoping Liu; Joanne Bruno; Adriana Heguy; Adam B Olshen; Nicholas D Socci; Julie Teruya-Feldstein; Frances Weis-Garcia; Wayne Tam; Rita Shaknovich; Ari Melnick; Juha P Himanen; R S K Chaganti; Hans-Guido Wendel
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

4.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.

Authors:  Y Tsujimoto; L R Finger; J Yunis; P C Nowell; C M Croce
Journal:  Science       Date:  1984-11-30       Impact factor: 47.728

5.  The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.

Authors:  L A O'Reilly; D C Huang; A Strasser
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

6.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Authors:  Georg Lenz; George W Wright; N C Tolga Emre; Holger Kohlhammer; Sandeep S Dave; R Eric Davis; Shannon Carty; Lloyd T Lam; A L Shaffer; Wenming Xiao; John Powell; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Lisa M Rimsza; Richard I Fisher; Dennis D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

7.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

8.  Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Authors:  Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

9.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Authors:  Jessica Okosun; Csaba Bödör; Jun Wang; Shamzah Araf; Cheng-Yuan Yang; Chenyi Pan; Sören Boller; Davide Cittaro; Monika Bozek; Sameena Iqbal; Janet Matthews; David Wrench; Jacek Marzec; Kiran Tawana; Nikolay Popov; Ciaran O'Riain; Derville O'Shea; Emanuela Carlotti; Andrew Davies; Charles H Lawrie; Andras Matolcsy; Maria Calaminici; Andrew Norton; Richard J Byers; Charles Mein; Elia Stupka; T Andrew Lister; Georg Lenz; Silvia Montoto; John G Gribben; Yuhong Fan; Rudolf Grosschedl; Claude Chelala; Jude Fitzgibbon
Journal:  Nat Genet       Date:  2013-12-22       Impact factor: 38.330

10.  Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.

Authors:  Elisa Oricchio; Giovanni Ciriello; Man Jiang; Michael H Boice; Jonathan H Schatz; Adriana Heguy; Agnes Viale; Elisa de Stanchina; Julie Teruya-Feldstein; Alyssa Bouska; Tim McKeithan; Chris Sander; Wayne Tam; Venkatraman E Seshan; Wing-Chung Chan; R S K Chaganti; Hans-Guido Wendel
Journal:  J Exp Med       Date:  2014-06-09       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.